New Advances in Metastatic Urothelial Cancer: A Narrative Review on Recent Developments and Future Perspectives

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Metastatic urothelial carcinoma (mUC) treatment historically relied on platinum-based chemotherapy.
• Recent advances include immune checkpoint inhibitors and fibroblast growth factor receptor (FGFR) inhibitors for specific genetic alterations.

Purpose of the Study:

• To review the evolving landscape of mUC treatment options.
• To provide insights into the molecular basis and mechanisms of novel therapies.
• To evaluate new therapeutic strategies for personalized treatment approaches.

Main Methods:

• Literature review of current and emerging treatments for mUC.
• Analysis of molecular targets and mechanisms of action for new agents.
• Evaluation of clinical trial data and regulatory approvals.

Main Results:

• Antibody-drug conjugates (ADCs) have emerged as a promising new class of therapy for mUC.
• Enfortumab vedotin and sacituzumab govitecan are leading ADCs with accelerated approvals.
• Numerous other ADCs are under investigation, indicating significant ongoing research.

Conclusions:

• ADCs represent a significant advancement and the "new frontier" in mUC treatment.
• These agents have the potential to transform future management of metastatic urothelial carcinoma.
• Personalized treatment strategies are becoming increasingly important in mUC therapy.